ArticleThe World Allergy Organization journal2012
WAO Guideline for the Management of Hereditary Angioedema.
Article in The World Allergy Organization journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Psychology and hereditary angioedema: A systematic review.Allergy and asthma proceedings · 2021Pooled it
- Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies.Orphanet journal of rare diseases · 2018Pooled it
- Brazilian Guidelines for Hereditary Angioedema Management - 2017 Update Part 1: Definition, Classification and Diagnosis.Clinics (Sao Paulo, Brazil) · 2018Guideline
- A consensus parameter for the evaluation and management of angioedema in the emergency department.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2014Guideline
- Trial
- Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.Orphanet journal of rare diseases · 2018Trial
- Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.Allergy · 2015Trial
- Trial
- Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency.BMC gastroenterology · 2014Trial
- Medical Malpractice in the Management of Angioedema: A Multidisciplinary Westlaw Analysis.World journal of otorhinolaryngology - head and neck surgery · 2026Article
- The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities.The World Allergy Organization journal · 2026Article
- Toward equitable and evidence-based care in Hereditary Angioedema: Time for inclusive global guidelines.The World Allergy Organization journal · 2026Article
- C1 Esterase Inhibitor Deficiency in an Indian Female: A Rare Case Report and a Review of Literature with Treatment Update.Current drug targets · 2026Review
- Urgent diagnosis of hereditary angioedema in the ICU and ED: the critical role of rapid complement testing - a case report.International journal of emergency medicine · 2025Article
- Hereditary angioedema diagnosis evaluation score (HADES): A new clinical scoring system for predicting hereditary angioedema with C1 inhibitor deficiency.The journal of allergy and clinical immunology. Global · 2025Article
- Erratum: Effect of Fresh Frozen Plasma Infusion on Hospital Length of Stay for Patients With Hereditary Angioedema.Journal of health economics and outcomes research · 2025Article
- Association between Toll-like receptor 9 signaling defect and developing post-infectious irritable bowel syndrome.Frontiers in immunology · 2025Article
- Erratum: Characteristics and Comorbidities Influencing Mortality Risk Among Hereditary Angioedema Patients.Journal of health economics and outcomes research · 2025Article
- Characteristics and Comorbidities Influencing Mortality Risk Among Hereditary Angioedema Patients.Journal of health economics and outcomes research · 2025Article
- Real-world evidence of the effectiveness and utilization of subcutaneous C1INH long-term prophylaxis in patients with HAE in Spain and Germany.Frontiers in immunology · 2025Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
: Hereditary Angioedema (HAE) is a rare disease and for this reason proper diagnosis and appropriate therapy are often unknown or not available for physicians and other health care providers. For this reason we convened a group of specialists that focus upon HAE from around the world to develop not only a consensus on diagnosis and management of HAE, but to also provide evidence based grades, strength of evidence and classification for the consensus. Since both consensus and evidence grading were adhered to the document meets criteria as a guideline. The outcome of the guideline is to improve diagnosis and management of patients with HAE throughout the world and to help initiate uniform care and availability of therapies to all with the diagnosis no matter where the residence of the individual with HAE exists.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.